Grace Therapeutics, Inc. Selling and Marketing Expense
Grace Therapeutics, Inc. (GRCE) reported Selling and Marketing Expense of $252.00 thousand for the 12-month period ending 2024-03-31, per its 10-K filed 2024-06-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2024-06-21
- Grace Therapeutics, Inc. selling and marketing expense for the quarter ending 2024-03-31 was $68.00K, a 30.61% decline year-over-year.
- Grace Therapeutics, Inc. selling and marketing expense for the quarter ending 2023-12-31 was $30.00K, a 85.44% decline year-over-year.
- Grace Therapeutics, Inc. selling and marketing expense for the quarter ending 2023-09-30 was $43.00K, a 68.38% decline year-over-year.
- Grace Therapeutics, Inc. selling and marketing expense for the quarter ending 2023-06-30 was $111.00K, a 49.77% decline year-over-year.
- Grace Therapeutics, Inc. selling and marketing expense for fiscal 2024 was $252.00K, a 61.88% decline from fiscal 2023.
- Grace Therapeutics, Inc. selling and marketing expense for fiscal 2023 was $661.00K, a 27.61% increase from fiscal 2022.
- Grace Therapeutics, Inc. selling and marketing expense for fiscal 2022 was $518.00K, a 54.64% decline from fiscal 2021.
- Grace Therapeutics, Inc. selling and marketing expense for fiscal 2021 was $1.14M, a 57.15% decline from fiscal 2020.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $98.00K derived: sum of 2 quarters · filed 2024-06-21 | $141.00K derived: sum of 3 quarters · filed 2024-06-21 | $252.00K 10-K · filed 2024-06-21 |
| 2023-12-31 | $30.00K 10-Q · filed 2024-02-12 | $73.00K derived: sum of 2 quarters · filed 2024-02-12 | $184.00K 10-Q · filed 2024-02-12 | $282.00K derived: sum of 4 quarters · filed 2024-06-21 |
| 2023-09-30 | $43.00K 10-Q · filed 2023-11-13 | $154.00K 10-Q · filed 2023-11-13 | $252.00K derived: sum of 3 quarters · filed 2024-06-21 | $458.00K derived: sum of 4 quarters · filed 2024-06-21 |
| 2023-06-30 | $111.00K 10-Q · filed 2023-08-11 | $209.00K derived: sum of 2 quarters · filed 2024-06-21 | $415.00K derived: sum of 3 quarters · filed 2024-06-21 | $551.00K derived: sum of 4 quarters · filed 2024-06-21 |
| 2023-03-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $304.00K derived: sum of 2 quarters · filed 2024-06-21 | $440.00K derived: sum of 3 quarters · filed 2024-06-21 | $661.00K 10-K · filed 2024-06-21 |
| 2022-12-31 | $206.00K 10-Q · filed 2024-02-12 | $342.00K derived: sum of 2 quarters · filed 2024-02-12 | $563.00K 10-Q · filed 2024-02-12 | $818.00K derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-09-30 | $136.00K 10-Q · filed 2023-11-13 | $357.00K 10-Q · filed 2023-11-13 | $612.00K derived: sum of 3 quarters · filed 2023-11-13 | $850.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $221.00K 10-Q · filed 2023-08-11 | $476.00K derived: sum of 2 quarters · filed 2023-08-11 | $714.00K derived: sum of 3 quarters · filed 2023-08-11 | $739.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-23 | $493.00K derived: sum of 2 quarters · filed 2023-06-23 | $518.00K derived: sum of 3 quarters · filed 2023-06-23 | $518.00K 10-K · filed 2023-06-23 |
| 2021-12-31 | $238.00K 10-Q · filed 2023-02-14 | $263.00K derived: sum of 2 quarters · filed 2023-02-14 | $263.00K 10-Q · filed 2023-02-14 | $329.00K derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-09-30 | $25.00K 10-Q · filed 2022-11-14 | $25.00K 10-Q · filed 2022-11-14 | $91.00K derived: sum of 3 quarters · filed 2022-11-14 | $317.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $66.00K derived: sum of 2 quarters · filed 2022-06-21 | $292.00K derived: sum of 3 quarters · filed 2022-06-21 | $426.00K derived: sum of 4 quarters · filed 2022-06-21 |
| 2021-03-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | $292.00K derived: sum of 2 quarters · filed 2022-06-21 | $426.00K derived: sum of 3 quarters · filed 2022-06-21 | $1.14M 10-K · filed 2022-06-21 |
| 2020-12-31 | $226.00K 10-Q · filed 2022-02-14 | $360.00K derived: sum of 2 quarters · filed 2022-02-14 | $1.08M 10-Q · filed 2022-02-14 | $1.64M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $134.00K 10-Q · filed 2021-11-10 | $850.00K 10-Q · filed 2021-11-10 | $1.41M derived: sum of 3 quarters · filed 2021-11-10 | $2.07M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $716.00K 10-Q · filed 2021-08-12 | $1.28M derived: sum of 2 quarters · filed 2021-08-12 | $1.94M derived: sum of 3 quarters · filed 2021-08-12 | $2.68M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $564.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-22 | $1.22M derived: sum of 2 quarters · filed 2021-06-22 | $1.97M derived: sum of 3 quarters · filed 2021-06-22 | $2.67M 10-K · filed 2021-06-22 |
| 2019-12-31 | $655.00K 10-Q · filed 2021-02-09 | $1.40M derived: sum of 2 quarters · filed 2021-02-09 | $2.10M 10-Q · filed 2021-02-09 | |
| 2019-09-30 | $746.00K 10-Q · filed 2020-11-16 | $1.45M 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $700.00K 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | $494.00K 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |